Join Mintz Levin and ML Strategies as we look ahead to 2017 and discuss priorities of the FDA and the potential impact on companies in the health care and life sciences industries.
Topics will include:
• President-elect Trump’s plans for FDA reform
• Expected health care activity in the 115th Congress
• Changing FDA regulatory priorities
• Practical implications for industry
To register, please click here.